Why β-Blockers Should Not Be Used as First Choice in Uncomplicated Hypertension

American Journal of Cardiology

Volumn 105, Issue 10, 2010, Pages 1433-1438

  De Caterina, Alberto Ranieri ^a   Leone, Antonio Maria ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DILTIAZEM; DIURETIC AGENT; LOSARTAN; METOPROLOL; NEBIVOLOL; PINDOLOL; PLACEBO; PROPRANOLOL; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT;

AIRWAY RESISTANCE; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; BLURRED VISION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEPRESSION; DREAM; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LETHARGY; METABOLIC DISORDER; MORTALITY; NIGHTMARE; NONHUMAN; ORGASM DISORDER; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; SIDE EFFECT; SLEEP DISORDER; STABLE ANGINA PECTORIS; STROKE; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; VISUAL HALLUCINATION; WEIGHT GAIN;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STROKE; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 77951667288     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.12.068     Document Type: Review

References (50)

1. Yusuf S., Peto R., Lewis J., Collins R., and Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27 (1985) 335-371
2. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., Grassi G., Heagerty A.M., Kjeldsen S.E., Laurent S., Narkiewicz K., Ruilope L., Rynkiewicz A., Schmieder R.E., Boudier H.A., Zanchetti A., Vahanian A., Camm J., De Caterina R., Dean V., Dickstein K., Filippatos G., Funck-Brentano C., Hellemans I., Kristensen S.D., McGregor K., Sechtem U., Silber S., Tendera M., Widimsky P., Zamorano J.L., Erdine S., Kiowski W., Agabiti-Rosei E., Ambrosioni E., Lindholm L.H., Viigimaa M., Adamopoulos S., Agabiti-Rosei E., Ambrosioni E., Bertomeu V., Clement D., Erdine S., Farsang C., Gaita D., Lip G., Mallion J.M., Manolis A.J., Nilsson P.M., O'Brien E., Ponikowski P., Redon J., Ruschitzka F., Tamargo J., van Zwieten P., Waeber B., and Williams B. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25 (2007) 1105-1187
3. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., and Roccella E.J. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
4. Berenson A. Big drug makers see sales decline with their image. The New York Times (November 15, 2005)
5. Kaboli P.J., Shivapour D.M., Henderson M.S., Barnett M.J., Ishani A., and Carter B.L. Patient and provider perceptions of hypertension treatment: do they agree?. J Clin Hypertens 9 (2007) 416-423
6. National Collaborating Centre for Chronic Conditions. Hypertension: Management of Hypertension in Adults in Primary Care: Partial Update (2006), Royal College of Physicians, London, United Kingdom
7. Lund-Johansen P. Hemodynamic consequences of long-term beta-blocker therapy: a 5-year follow-up study of atenolol. J Cardiovasc Pharmacol 1 (1979) 487-495
8. Man in't Veld A.J., van den Meiracker A.H., and Schalekamp M.A. Do beta blockers really increase peripheral vascular resistance?. Review of the literature and new observations under basal conditions. Am J Hypertens 1 (1988) 91-96
9. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 291 (1985) 87-104
10. Coope J., and Warrender T.S. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 293 (1986) 1145-1151
11. Dahlöf B., Lindholm L.H., Hanson L., Scherstén B., Ekbom T., and Wester P.O. Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP-Hypertension). Lancet 338 (1991) 1281-1285
12. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 304 (1992) 405-412
13. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 24 (1993) 543-548
14. Eriksson S., Olofsson B.O., and Wester P.O. Atenolol in the secondary prevention after stroke. Cerebrovasc Dis 5 (1995) 21-25
15. Hansson L., Hedner T., Lund-Johansen P., Kjeldsen S.E., Lindholm L.H., Syvertsen J.O., Lanke J., de Faire U., Dahlöf B., and Karlberg B.E. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 356 (2000) 359-365
16. Dahlöf B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Wedel H., and LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
17. Dahlöf B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O'Brien E., Ostergren J., and ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005) 895-906
18. Carlberg B., Samuelsson O., and Lindholm L.H. Atenolol in hypertension: is it a wise choice?. Lancet 364 (2004) 1684-1689
19. Lindholm L.H., Carlberg B., and Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension?. A meta-analysis. Lancet 366 (2005) 1545-1553
20. Collins R., Peto R., MacMahon S., Hebert P., Fiebach N.H., Eberlein K.A., Godwin J., Qizilbash N., Taylor J.O., and Hennekens C.H. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335 (1990) 827-838
21. Wiysonge C.S., Bradley H., Mayosi B.M., Maroney R., Mbewu A., Opie L.H., and Volmink J. Beta-blockers for hypertension. Cochrane Database Syst Rev (2007) 1-47
22. Khan N., and McAlister F.A. Re-examining the efficacy of β-blockers for the treatment of hypertension: a meta-analysis. CMAJ 174 (2006) 1737-1742
23. Messerli F.H., Grossman E., and Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?. A systematic review. JAMA 279 (1998) 1903-1907
24. Messerli F.H. Antihypertensive therapy: beta-blockers and diuretics. Why do physicians not always follow guidelines?. Proc Baylor Univ Med Center 13 (2000) 128-131
25. Fox K., Borer J.S., Camm A.J., Danchin N., Ferrari R., Lopez Sendon J.L., Steg P.G., Tardif J.C., Tavazzi L., Tendera M., and Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 50 (2007) 823-830
26. Bangalore S., Sawhney S., and Messerli F.H. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 52 (2008) 1482-1489
27. Poulter N.R., Dobson J.E., Sever P.S., Dahlöf B., Wedel H., Campbell N.R.C., and ASCOT Investigators. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol 54 (2009) 1154-1161
28. Williams B., Lacy P.S., Thom S.M., Cruickshank K., Stanton A., Collier D., Hughes A.D., Thurston H., O'Rourke M., CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, and CAFE Steering CommitteeWriting Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113 (2006) 1213-1225
29. Okin P.M., Devereux R.B., Jern S., Kjeldsen S.E., Julius S., Nieminen M.S., Snapinn S., Harris K.E., Aurup P., Edelman J.M., Wedel H., Lindholm L.H., Dahlöf B., and LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292 (2004) 2343-2349
30. Dahlof B., Pennert K., and Hansson L. Regression of left ventricular hypertrophy-a meta-analysis. Clin Exp Hypertens A 14 (1992) 173-180
31. Ciulla M.M., Paliotti R., Esposito A., Dìez J., López B., Dahlöf B., Nicholls M.G., Smith R.D., Gilles L., Magrini F., and Zanchetti A. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation 110 (2004) 552-557
32. Elliott W.J., and Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369 (2007) 201-207
33. Lithell H.O. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 14 (1991) 203-209
34. Pischon T., and Sharma A.M. Use of beta-blockers in obesity hypertension: potential role of weight gain. Obes Rev 2 (2001) 275-280
35. Schiffrin E.L., Pu Q., and Park J.B. Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients. Am J Hypertens 15 (2002) 105-110
36. Smith R.D., Yokoyama H., Averill D.B., Cooke L., Brosnihan K.B., Schiffrin E.L., and Ferrario C.M. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (the VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs 6 (2006) 335-342
37. Schiffrin E.L., Park J.B., and Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens 20 (2002) 71-78
38. Frishman W.H. Carvedilol. N Engl J Med 339 (1998) 1759-1765
39. Opie L., and Yusuf S. Beta-blocking agents. In: Opie L.H., and Gersh B. (Eds). Drugs for the Heart. 6th ed. (2005), W. B. Saunders, Philadelphia, Pennsylvania 1-32
40. Messerli F.H., and Grossman E. Beta-blockers in hypertension: is carvedilol different?. Am J Cardiol 93 suppl (2004) 7B-12B
41. Messerli F.H., Bell D.S., Fonseca V., Katholi R.E., McGill J.B., Phillips R.A., Raskin P., Wright Jr. J.T., Bangalore S., Holdbrook F.K., Lukas M.A., Anderson K.M., Bakris G.L., and GEMINI Investigators. Body weight changes with beta-blocker use: results from GEMINI. Am J Med 120 (2007) 610-615
42. Poole-Wilson P.A., Swedberg K., Cleland J.G., Di Lenarda A., Hanrath P., Komajda M., Lubsen J., Lutiger B., Metra M., Remme W.J., Torp-Pedersen C., Scherhag A., Skene A., and Carvedilol or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
43. Giugliano D., Acampora R., Marfella R., De Rosa N., Ziccardi P., Ragone R., De Angelis L., and D'Onofrio F. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 126 (1997) 955-959
44. Broeders M.A., Doevendans P.A., Bekkers B.C., Bronsaer R., van Gorsel E., Heemskerk J.W., Egbrink M.G., van Breda E., Reneman R.S., and van Der Zee R. Nebivolol: a third-generation β-blocker that augments vascular nitric oxide release. Endothelial β2-adrenergic receptor-mediated nitric oxide production. Circulation 102 (2000) 677-682
45. Tzemos N., Lim P.O., and MacDonald T.M. Nebivolol reverses endothelial dysfunction in essential hypertension. A randomised, double blind crossover study. Circulation 104 (2001) 511-514
46. Fratta Pasini A., Garbin U., Nava M.C., Stranieri C., Davoli A., Sawamura T., Lo Cascio V., and Cominacini L. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 23 (2005) 589-596
47. Dessy C., Saliez J., Ghisdal P., Daneau G., Lobysheva I.I., Frérart F., Belge C., Jnaoui K., Noirhomme P., Feron O., and Balligand J.L. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 112 (2005) 1198-1205
48. Pasini A.F., Garbin U., Stranieri C., Boccioletti V., Mozzini C., Manfro S., Pasini A., Cominacini M., and Cominacini L. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens 21 (2008) 1251-1257
49. Mahmud A., and Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 21 (2008) 663-667
50. Fogari R., Derosa G., Ferrari I., Corradi L., Zoppi A., Lazzari P., Santoro T., Preti P., and Mugellini A. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 1 (1997) 753-757